Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements

Molecular and Cellular Endocrinology

Volumn 299, Issue 2, 2009, Pages 204-211

  Ball, Lonnele J ^a   Levy, Nitzan ^a   Zhao, Xiaoyue ^b   Griffin, Chandi ^a   Tagliaferri, Mary ^b   Cohen, Isaac ^b   Ricke, William A ^c   Speed, Terence P ^d,e   Firestone, Gary L ^d   Leitman, Dale C ^a,d  

^a Center for Reproductive Sciences   (United States)

^b Bionovo Inc   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Estradiol; Estrogen receptor; Gene regulation; Microarray; Raloxifene; Selective estrogen receptor modulator; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ARTICLE; CANCER CELL; CELL STRAIN MCF 7; CELL TYPE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENDOMETRIUM; FEMALE; GENE CONTROL; HELA CELL; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; UTERINE CERVIX CANCER;

CELL LINE, TUMOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; GENE EXPRESSION REGULATION; HUMANS; ORGAN SPECIFICITY; RALOXIFENE; RECEPTORS, ESTROGEN; REGULATORY SEQUENCES, NUCLEIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 58649088924     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.10.050     Document Type: Article

References (38)

1. Beissbarth T., and Speed T.P. GOstat: find statistically overrepresented gene ontologies within a group of genes. Bioinformatics 20 (2004) 1464-1465
2. Carroll J.S., Liu X.S., Brodsky A.S., Li W., Meyer C.A., Szary A.J., Eeckhoute J., Shao W., Hestermann E.V., Geistlinger T.R., Fox E.A., Silver P.A., and Brown M. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122 (2005) 33-43
3. Cummings S., Eckert S., Krueger K., Grady D., Powles T., Cauley J., Norton L.T.N., Bjarnason N., Morrow M., ME L., Black D., Glusman J., Costa A., and Jordan V. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 281 (1999) 2189-2197
4. Dahlman-Wright K., Cavailles V., Fuqua S.A., Jordan V.C., Katzenellenbogen J.A., Korach K.S., Maggi A., Muramatsu M., Parker M.G., and Gustafsson J.A. International union of pharmacology. LXIV. Estrogen receptors. Pharmacol. Rev. 58 (2006) 773-781
5. Dudoit S., Shaffer J.P., and Boldrick J.C. Multiple hypothesis testing in microarray experiments. Stat. Sci. 18 (2003) 71-103
6. Dutertre M., and Smith C.L. Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains. Mol. Endocrinol. 17 (2003) 1296-1314
7. Eisen M.B., Spellman P.T., Brown P.O., and Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 14863-14868
8. Ettinger B., Black D., Mitlak B., Knickerbocker R., Nickelsen T., Genant H., Christiansen C., and Delmas P. Reduction of vertebral fracture risk in postmenopausal women with osteoprosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 282 (1999) 637-644
9. Feng W., Ribeiro R.C., Wagner R.L., Nguyen H., Apriletti J.W., Fletterick R.J., Baxter J.D., Kushner P.J., and West B.L. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 280 (1998) 1747-1749
10. Fisher B., Costantino J., Redmond C., Fisher E., Wickerham L., and Cronin W. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86 (1994) 527-537
11. Grady D., Cauley J.A., Geiger M.J., Kornitzer M., Mosca L., Collins P., Wenger N.K., Song J., Mershon J., and Barrett-Connor E. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J. Natl. Cancer Inst. 100 (2008) 854-861
12. Heldring N., Pike A., Andersson S., Matthews J., Cheng G., Hartman J., Tujague M., Strom A., Treuter E., Warner M., and Gustafsson J.A. Estrogen receptors: how do they signal and what are their targets. Physiol. Rev. 87 (2007) 905-931
13. Jordan V.C. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 5 (2004) 207-213
14. Kian Tee M., Rogatsky I., Tzagarakis-Foster C., Cvoro A., An J., Christy R.J., Yamamoto K.R., and Leitman D.C. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors {alpha} and {beta}. Mol. Biol. Cell 15 (2004) 1262-1272
15. Koehler K.F., Helguero L.A., Haldosen L.A., Warner M., and Gustafsson J.A. Reflections on the discovery and significance of estrogen receptor beta. Endocr. Rev. 26 (2005) 465-478
16. Kushner P.J., Agard D.A., Greene G.L., Scanlan T.S., Shiau A.K., Uht R.M., and Webb P. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74 (2000) 311-317
17. Laganiere J., Deblois G., Lefebvre C., Bataille A.R., Robert F., and Giguere V. From the cover: location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 11651-11656
18. Levy N., Tatomer D., Herber C.B., Zhao X., Tang H., Sargeant T., Ball L.J., Summers J., Speed T.P., and Leitman D.C. Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene. Mol. Endocrinol. 22 (2008) 287-303
19. Levy N., Zhao X., Tang H., Jaffe R.B., Speed T.P., and Leitman D.C. Multiple transcription factor elements collaborate with estrogen receptor {alpha} to activate an inducible estrogen response element in the NKG2E gene. Endocrinology 148 (2007) 3449-3458
20. Love R.R., Mazess R.B., Tormey D.C., Barden H.S., Newcomb P.A., and Jordan V.C. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res. Treat. 12 (1988) 297-302
21. MacGregor J.I., and Jordan V.C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 50 (1998) 151-196
22. Martinez Lage J.M., Oliveros-Cid A., and Martinez-Lage P. Estrogens and Alzheimer's disease: rationale, promises, and facts. Med. Clin. (Barc) 114 (2000) 747-755
23. Mersereau J.E., Levy N., Staub R.E., Baggett S., Zogric T., Chow S., Ricke W.A., Tagliaferri M., Cohen I., Bjeldanes L.F., and Leitman D.C. Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol. Cell Endocrinol. 283 (2008) 49-57
24. Nettles K.W., and Greene G.L. Ligand control of coregulator recruitment to nuclear receptors. Annu. Rev. Physiol. 67 (2005) 309-333
25. O'Regan R.M., and Jordan V.C. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol. 3 (2002) 207-214
26. Paech K., Webb P., Kuiper G., Nilsson S., gustafsson J.-A., Kushner P., and Scanlan T. Differential ligand activation of estrogen receptors ERa and ERb at API sites. Science 277 (1997) 1508-1510
27. Ricke W.A., Ishii K., Ricke E.A., Simko J., Wang Y., Hayward S.W., and Cunha G.R. Steroid hormones stimulate human prostate cancer progression and metastasis. Int. J. Cancer 118 (2006) 2123-2131
28. Shang Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat. Rev. Cancer 6 (2006) 360-368
29. Shang Y., and Brown M. Molecular determinants for the tissue specificity of SERMs. Science 295 (2002) 2465-2468
30. Shang Y., Hu X., DiRenzo J., Lazar M.A., and Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103 (2000) 843-852
31. Shelly W., Draper M.W., Krishnan V., Wong M., and Jaffe R.B. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet. Gynecol. Surv. 63 (2008) 163-181
32. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., and Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 (1998) 927-937
33. Smith C.L., and O'Malley B.W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25 (2004) 45-71
34. Torchia J., Glass C., and Rosenfeld M.G. Co-activators and co-repressors in the integration of transcriptional responses. Curr. Opin. Cell. Biol. 10 (1998) 373-383
35. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., Bevers T.B., Fehrenbacher L., Pajon Jr. E.R., Wade III J.L., Robidoux A., Margolese R.G., James J., Lippman S.M., Runowicz C.D., Ganz P.A., Reis S.E., McCaskill-Stevens W., Ford L.G., Jordan V.C., and Wolmark N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 295 (2006) 2727-2741
36. Webb P., Lopez G.N., Uht R.M., and Kushner P.J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol. 9 (1995) 443-456
37. Webb P., Nguyen P., Shinsako J., Anderson C., Feng W., Nguyen M.P., Chen D., Huang S.M., Subramanian S., McKinerney E., Katzenellenbogen B.S., Stallcup M.R., and Kushner P.J. Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol. Endocrinol. 12 (1998) 1605-1618
38. Wu Z., and Irizarry R.A. Stochastic models inspired by hybridization theory for short oligonucleotide arrays. J. Comput. Biol. 12 (2005) 882-893